Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 21 Nov 2022
Medicare 2.0 - a vision for the future of America’s health insurance plan
21 November 2022 - Medicare is one of the great successes in American social policy. It provides universal health insurance to ...
Posted by Michael Wonder on 21 Nov 2022
TLV subsidises drugs against cystic fibrosis
18 November 2022 - The Dental and Pharmaceutical Benefits Agency, TLV, has decided that the drugs Kaftrio, Kalydeco and Symkevi, ...
Posted by Michael Wonder on 21 Nov 2022
US FDA accepts for priority review the biologics license application for epcoritamab (DuoBody-CD3xCD20) for the treatment of relapsed/refractory large B-cell lymphoma
21 November 2022 - The application is supported by data from EPCORE NHL-1 Phase 1/2 trial evaluating the safety and preliminary ...
Posted by Michael Wonder on 21 Nov 2022
New Quality Innovation Expert Group supports medicine innovation
21 November 2022 - The EMA has established a Quality Innovation Expert Group to support innovative approaches for the development, ...
Posted by Michael Wonder on 21 Nov 2022
Moderna applies to Swissmedic for authorisation of a second bivalent COVID-19 vaccine
18 November 2022 - Application submitted for Spikevax Bivalent Original / Omicron BA.4-5 (mRNA-1273.222) ...
Posted by Michael Wonder on 21 Nov 2022
Adjustment for baseline characteristics in randomised clinical trials
17 November 2022 - The purpose of randomisation in clinical trials is to ensure that there are no systematic differences between ...
Posted by Michael Wonder on 21 Nov 2022
Bristol Myers Squibb warns US price reforms will dent drug development
20 November 2022 - Biggest shake-up in pharma pricing in decades prompts companies to shelve some potential therapies. ...
Posted by Michael Wonder on 21 Nov 2022
Are patient satisfaction instruments harming both patients and physicians?
17 November 2022 - Patient satisfaction surveys have become a mainstay of the health care experience. ...
Posted by Michael Wonder on 21 Nov 2022
Big pharma may have to reveal government deals in WHO's draft pandemic rules
17 November 2022 - Pharmaceutical companies could be made to disclose prices and deals agreed for any products they make ...
Posted by Michael Wonder on 21 Nov 2022
FDA cancer chief wants quicker ways to pull failed drugs
17 November 2022 - Makena highlights need to make system more nimble. ...
Posted by Michael Wonder on 21 Nov 2022
'Heartbreaking': parents of sick 11 month old want greater meningitis awareness
19 November 2022 - A cough quickly turned into a “horrible” few weeks for an Auckland family whose infant son ...
Posted by Michael Wonder on 21 Nov 2022
Getting the price right: lessons for Medicare price negotiation from peer countries
9 November 2022 - The US pays more for brand-name prescription drugs than any other country and new legislation from August ...
Posted by Michael Wonder on 20 Nov 2022
PHARMAC welcomes Myeloma NZ as first patient advocacy group to present to PTAC
21 November 2022 - Myeloma New Zealand presented directly to PHARMAC’s Pharmacology and Therapeutics Advisory Committee (PTAC) on Thursday, making ...
Posted by Michael Wonder on 19 Nov 2022
Inflation Reduction Act drug pricing provisions aren’t at all like price controls in Europe
18 November 2022 - The opposition to the prescription drug pricing provisions in the Inflation Reduction Act can be hyperbolic. ...
Posted by Michael Wonder on 19 Nov 2022
COVID-19 vaccine safety report (17 November 2022)
17 November 2022 - To 13 November 2022, the TGA has received 706 reports which have been assessed as likely to ...